Medical Advancements - A new era of cancer treatment is emerging [1] - Stage-four lung cancer patient survived for ten years [1]

Financial Data and Key Metrics Changes - For the second quarter of 2025, the company reported revenues of approximately $422,000 from commercial sales of the RenovaCATH device, driven by new customer purchase orders and early repeat orders [17] - Research and development expenses were $1.4 million, reflecting a $100,000 decrease from the same quarter year over year [17] - The company ended the quarter with $12.3 million in cash and cash equivalents [17] Business Line Data and Key Metrics Changes - The RenovaCATH device achieved over $400,000 in sales in the second quarter, marking a significant accomplishment shortly after its launch [7][11] - The company has randomized 95 patients in the Phase three TIGER PACT trial, with 61 events occurring, keeping it on track to complete enrollment later this year or early next year [10][13] Market Data and Key Metrics Changes - The initial U.S. total addressable market for the RenovaCATH device is estimated at $400 million in peak annual sales opportunity [12] - The company believes there is potential for a several billion dollar total addressable market as it expands into additional cancer applications [12] Company Strategy and Development Direction - The company aims to transform patient outcomes through safer, more effective targeted therapy, particularly for difficult-to-treat cancers like locally advanced pancreatic cancer [10] - The company is focused on building commercialization momentum while maintaining a lean operational structure [11] - The company plans to explore international markets after establishing a strong presence in the U.S. [41] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the positive recommendation from the independent data monitoring committee (DMC) to continue the TIGER PACT trial, indicating confidence in the trial's potential outcomes [9][13] - The company anticipates a ramp-up in enrollment pace due to the addition of larger cancer centers [29] Other Important Information - The company launched a multicenter post-marketing registry study called PANTHER to evaluate the safety and effectiveness of the RenovaCATH device in real-world clinical settings [14] - The company is exploring the use of the RenovaCATH device for various solid tumors beyond pancreatic cancer, including cholangiocarcinoma and non-small cell lung cancer [52][53] Q&A Session Summary Question: Clarification on trial patient numbers - Management confirmed that the DMC's feedback was positive, and the trial will maintain the same sample size without adding patients [22] Question: Timing for data from the PANTHER trial - Management indicated that data from the PANTHER study will be published as interesting findings arise, without a specific timeline [31] Question: Update on partnerships with top cancer centers - Management reported that they are currently in 13 hospitals with approvals to purchase the device, with four centers already treating patients [39] Question: Revenue from clinical studies vs. commercial sales - Management clarified that the reported revenue of $422,000 is from new customers outside of the clinical trial, with no revenue recognized from the TIGER PACT trial [46] Question: Plans for international market expansion - Management stated that while the focus is currently on the U.S. market, there are plans to explore international opportunities in the future [41] Question: Gross margins sustainability - Management expressed confidence that gross margins could increase towards the 70% to 90% range as the company scales [72] Question: Future revenue expectations - Management anticipates growth throughout the year, with a significant ramp-up expected in 2026 as the sales team is fully established [76]

Core Insights - Aethlon Medical has made significant progress in its Australian oncology trial, completing the first treatment cohort and amending the protocol to broaden patient eligibility [1][2][5] - The company reported a 31.6% reduction in operating expenses for the fiscal first quarter, enhancing operational efficiency [10][16] - Promising preclinical data supports the potential of the Hemopurifier in treating various conditions, including Long COVID [10][12][14] Clinical Progress - The first treatment cohort in the Australian trial involved patients with solid tumors unresponsive to PD-1 inhibitors, with no serious adverse events reported [3][4] - The independent Data Safety Monitoring Board recommended advancing to the second treatment cohort, which will involve two Hemopurifier treatments within a week [4] - The trial aims to assess safety and the potential to improve the body's natural ability to attack tumor cells by reducing extracellular vesicle concentrations [7][8] Financial Performance - As of June 30, 2025, Aethlon had a cash balance of approximately $3.8 million [15] - Consolidated operating expenses for the quarter were approximately $1.8 million, down from $2.6 million in the same period last year [16][20] - The operating loss for the quarter decreased to $1.8 million compared to $2.6 million for the same period in 2024 [20] Preclinical and Research Developments - Aethlon's preclinical study demonstrated a 98.5% removal of platelet-derived extracellular vesicles from healthy human plasma during a simulated 4-hour treatment [10][11] - The company is collaborating with UCSF to explore the Hemopurifier's potential applications in Long COVID, with initial findings presented at a recent symposium [12][13][14] Strategic Decisions - Aethlon decided not to proceed with a planned oncology trial in India due to extended timelines and costs, allowing the company to focus on its ongoing trial in Australia [9] - The amended protocol for the Australian trial reflects current standards of care, expanding eligibility to patients receiving various treatment regimens that include anti-PD-1 agents [5]

Funding & Investment - Strand Therapeutics, an MIT spinout, secured $153 million in funding [1] Cancer Research & Development - The funding aims to develop technology that makes cancerous tumors light up [1]

Funding & Investment - Strand Therapeutics, an MIT spinout, raised $153 million [1] Industry Focus - The company aims to make cancerous tumors light up [1]

MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Up https://t.co/WcV2bSWCgI https://t.co/WcV2bSWCgI ...

MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Up https://t.co/2X76G5Bpb5 https://t.co/2X76G5Bpb5 ...

Funding - Strand Therapeutics 完成 1.53 亿美元融资 [1] Industry Focus - 公司致力于使癌性肿瘤发光 [1]

Financial Data and Key Metrics Changes - For Q2 2025, revenue totaled $70,000 from a research license agreement with Catalent, compared to no revenue in Q2 2024 [9] - Operating expenses decreased to $4,900,000 in Q2 2025 from $5,500,000 in Q2 2024, a reduction of 10.6% [10] - Net losses were $4,700,000 for Q2 2025, down from $5,000,000 in Q2 2024, indicating progress in capital management [11] Business Line Data and Key Metrics Changes - Research and development expenses were approximately $2,300,000 in Q2 2025, down from $2,600,000 in Q2 2024, a decrease of 13.4% [10] - General and administrative expenses were approximately $2,700,000 in Q2 2025, compared to $2,900,000 in Q2 2024, a decrease of 8.1% [10] Market Data and Key Metrics Changes - The company anticipates a data-rich period in the next twelve months with several key milestones on the horizon [6] Company Strategy and Development Direction - The company is focused on developing its proprietary cyclic internalizing RGD peptide product candidate, certepatide, for advanced solid tumors and other difficult-to-treat diseases [12] - Recent collaborations include a research agreement with Catalent and a strategic alliance with GATC Health to enhance drug discovery [24][25] - The company has secured multiple special designations from both the FDA and EMA for certepatide [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of certepatide based on positive preliminary results from ongoing clinical trials [6][28] - The company is preparing for a Phase III trial based on FDA agreement on the protocol, with an expected enrollment of 650 to 900 patients [30] Other Important Information - The company has extended its patent protection for certepatide until March 2040, enhancing its intellectual property portfolio [25] - The company believes available funds will support current operations into 2026 [11] Q&A Session Summary Question: Insights on the ASCEND trial Phase III protocol - Management confirmed a tacit agreement with the FDA on the structure of an open-label Phase III trial, potentially including 650 to 900 patients [30] Question: Expectations on spending and runway extension - Management indicated that spending may see a modest decrease over time, depending on the initiation of the Phase III trial and results from ongoing trials [33] Question: Inclusion of future license revenues in projections - Management clarified that current projections only include a small contribution from the New Jersey sale of NOLs, with no anticipated capital raises included [36] Question: Changes in patent coverage - Management explained that the latest patent recognized specific intellectual property around the composition of matter of certepatide, securing the intellectual property portfolio [38] Question: Comparison of regulatory environments in the US and China - Management stated that it is difficult to compare the two regulatory environments due to the unique relationships Chinese companies have with their authorities [40]

MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Up https://t.co/x30NSJZwz0 https://t.co/x30NSJZwz0 ...